Literature DB >> 22684858

Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.

Giovanni Musso1, Maurizio Cassader, Franco De Michieli, Floriano Rosina, Fabio Orlandi, Roberto Gambino.   

Abstract

UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) ranges from simple steatosis (SS) to nonalcoholic steatohepatitis (NASH). Though liver-related risk seems confined to NASH, it is currently unclear whether NASH has a higher risk of cardiovascular disease (CVD) and diabetes than SS as a result of the coexistence of obesity and other cardiometabolic confounders. Adipose tissue is an emerging modulator of liver disease in NAFLD and of cardiometabolic disease in the general population. We evaluated in SS and NASH (1) glucose homeostasis and cardiovascular risk profile and (2) the effect of adipose tissue dysfunction, assessed in fasting conditions and postprandially, on liver injury, glucose and lipoprotein metabolism, and markers of early atherosclerosis. Forty nonobese, nondiabetic, normolipidemic biopsy-proven NAFLD patients (20 with SS and 20 with NASH) and 40 healthy subjects, matched for overall/abdominal adiposity and metabolic syndrome, underwent an oral fat load test, with measurement of plasma triglyceride-rich lipoproteins, oxidized low-density lipoproteins, adipokines, and cytokeratin-18 fragments, and an oral glucose tolerance test with minimal model analysis to yield glucose homeostasis parameters. Circulating endothelial adhesion molecules were measured, and adipose tissue insulin resistance (adipose IR) index and visceral adiposity index were calculated. Despite similar fasting values, compared to SS, NASH showed a more atherogenic postprandial lipoprotein profile, an altered adipokine response (i.e., higher resistin increase and an adiponectin fall), and hepatocyte apoptosis activation after fat ingestion. Adipose IR index, endothelial adhesion molecules, and hepatic insulin resistance progressively increased across NAFLD stages. NASH, but not SS, showed an impaired pancreatic β-cell function. On multiple regression analysis, adipose IR index and postprandial adiponectin independently predicted liver histology and altered cardiometabolic parameters.
CONCLUSION: Adipose tissue dysfunction, including a maladaptive adipokine response to fat ingestion, modulates liver injury and cardiometabolic risk in NAFLD.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684858     DOI: 10.1002/hep.25739

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  41 in total

1.  The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial.

Authors:  Yumie Takeshita; Toshinari Takamura; Masao Honda; Yuki Kita; Yoh Zen; Ken-ichiro Kato; Hirofumi Misu; Tsuguhito Ota; Mikiko Nakamura; Kazutoshi Yamada; Hajime Sunagozaka; Kuniaki Arai; Tatsuya Yamashita; Eishiro Mizukoshi; Shuichi Kaneko
Journal:  Diabetologia       Date:  2014-01-10       Impact factor: 10.122

Review 2.  Body composition assessment for the definition of cardiometabolic risk.

Authors:  M C Amato; V Guarnotta; C Giordano
Journal:  J Endocrinol Invest       Date:  2013-04-23       Impact factor: 4.256

3.  Ezetimibe in the balance: can cholesterol-lowering drugs alone be an effective therapy for NAFLD?

Authors:  Giovanni Musso
Journal:  Diabetologia       Date:  2014-02-20       Impact factor: 10.122

4.  Nonalcoholic Steatohepatitis (NASH) Is Associated with a Decline in Pancreatic Beta Cell (β-Cell) Function.

Authors:  Mohammad S Siddiqui; Kai L Cheang; Velimir A Luketic; Sherry Boyett; Michael O Idowu; Kavish Patidar; Puneet Puri; Scott Matherly; Richard T Stravitz; Richard K Sterling; Arun J Sanyal
Journal:  Dig Dis Sci       Date:  2015-03-18       Impact factor: 3.199

5.  The therapeutic effects of bee venom on some metabolic and antioxidant parameters associated with HFD-induced non-alcoholic fatty liver in rats.

Authors:  Mervat Y Hanafi; Eman L M Zaher; Soha E M El-Adely; Ahmed Sakr; Ahmed H M Ghobashi; Madiha H Hemly; Amani H Kazem; Maher A Kamel
Journal:  Exp Ther Med       Date:  2018-04-03       Impact factor: 2.447

Review 6.  Ghrelin-ghrelin O-acyltransferase system in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Shao-Ren Zhang; Xiao-Ming Fan
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

7.  Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.

Authors:  Ren-Nan Feng; Shan-Shan Du; Cheng Wang; Yan-Chuan Li; Li-Yan Liu; Fu-Chuan Guo; Chang-Hao Sun
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

Review 8.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

9.  Serum ferritin is associated with non-alcoholic fatty liver disease and decreased Β-cell function in non-diabetic men and women.

Authors:  Kristina M Utzschneider; Anna Largajolli; Alessandra Bertoldo; Santica Marcovina; James E Nelson; Matthew M Yeh; Kris V Kowdley; Steven E Kahn
Journal:  J Diabetes Complications       Date:  2013-11-26       Impact factor: 2.852

Review 10.  Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.

Authors:  Daniel Ferguson; Brian N Finck
Journal:  Nat Rev Endocrinol       Date:  2021-06-15       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.